The effects of rapamycin on regulatory T cells: Its potential time-dependent role in inducing transplant tolerance

Immunology Letters

Volumn 162, Issue 1, 2015, Pages 74-86

  Shan, Juan ^a   Feng, Li ^a   Li, Youping ^a,b   Sun, Guixiang ^a   Chen, Xuelu ^a   Chen, Peng ^a  

^a SICHUAN UNIVERSITY   (China)

^b Chinese Evidence Based Medicine Centre   (China)

Author keywords

Rapamycin; Regulatory T cells; Systematic review; Time dependent effects; Tolerance induction; Transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

DRUG EFFECT; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE COUNT; META ANALYSIS; ORGAN TRANSPLANTATION; TIME; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; ORGAN TRANSPLANTATION; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84908432145     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2014.07.006     Document Type: Review

References (73)

1. Shan J., Guo Y., Luo L., Lu J., Li C., Zhang C., et al. Do CD4+Foxp3+ Treg cells correlate with transplant outcomes: a systematic review on recipients of solid organ transplantation. Cell Immunol 2011, 270:5-12.
2. Miroux C., Morales O., Ghazal K., Othman S.B., de Launoit Y., Pancré V., et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation 2012, 94(2):123-131.
3. Kahan B.D., Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation 2001, 72:1181-1193.
4. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
5. Gao W., Lu Y., El Essawy B., Oukka M., Kuchroo V.K., Strom T.B. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007, 7(7):1722-1732.
6. Wang Y., Camir G., Lin Y., Froicu M., Deng S., Shlomchik W.D. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol 2011, 186:2809-2818.
7. Xu G., Wang L., Chen W., Xue F., Bai X., Liang L. Rapamycin and tacrolimus differentially modulate acute graft-versus-host disease in rats after liver transplantation. Liver Transplant 2010, 16(3):357-363.
8. Lu L., Qian X.F., Rao J.H., Wang X.H., Zheng S.G., Zhang F. Rapamycin promotes the expansion of CD4+Foxp3+ regulatory T cells after liver transplantation. Transplant Proc 2010, 42:1755-1757.
9. Wang G.Y., Yang Y., Li H., Zhang J., Li M.R., Zhang Q. Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4+CD25+Foxp3+ regulatory T cell expansion. Hepatol Res 2012, 42:192-202.
10. Strauss L., Whiteside T.L., Knights A., Bergmann C., Knuth A., Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007, 178:320-329.
11. Strauss L., Czystowska M., Szajnik M., Mandapathil M., Whiteside T.L. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLos ONE 2009, 4(6):e5994.
12. Lim D.G., Koo S.K., Park Y.H., Kim Y., Kim H.M., Park C.S. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4+CD25+Foxp3+ regulatory T cells in allotransplantation. Transplantation 2010, 89:928-936.
13. Ma A., Qi S., Song L., Hu Y., Dun H., Massicotte E. Adoptive transfer of CD4+CD25+ regulatory cells combined with low-dose sirolimus and anti-thymocyte globulin delays acute rejection of renal allografts in Cynomolgus monkeys. Int Immunopharmacol 2011, 11(5):618-629.
14. Ma A., Qi S., Wang Z., Massicotte E., Dupuis M., Daloze P. Combined therapy of CD4+CD25+ regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice. Int Immunopharmacol 2009, 9:553-563.
15. Keever-Taylor C.A., Browning M.B., Johnson B.D., Truitt R.L., Bredeson C.N., Behn B. Rapamycin enriches for CD4+CD25+CD27+ Foxp3+ regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007, 9(2):144-157.
16. Basu S., Golovina T., Mikheeva T., June C.H., Riley J.L. Cutting edge: Foxp3-mediated induction of Pim-2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008, 180:5794-5798.
17. San Segundo D., Fernández-Fresnedo G., Gago M., Beares I., Ruiz-Criado J., González M. Number of peripheral blood regulatory T cells and lymphocyte activation at 3 months after conversion to mtor inhibitor therapy. Transplant Proc 2010, 42(8):2871-2873.
18. Korczak-Kowalska G., Wierzbicki P., Bocian K., Klosowska D., Niemczyk M., Wyzgal J., et al. The influence of immuosuppressive therapy on the development of CD4+CD25+T cells after renal transplantation. Transplant Proc 2007, 39(9):2721-2723.
19. Noris M., Casiraghi F., Todeschini M., Cravedi P., Cugini D., Monteferrante G., et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007, 18(3):1007-1018.
20. Ruggenenti P., Perico N., Gotti E., Cravedi P., D'Agati V., Gagliardini E., et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007, 84(8):956-964.
21. Hendrikx T.K., Van Gurp E.A.F.J., Sewgobind V.D.K.D., Mol W.M., Schoordijk W., Klepper M., et al. Generation of donor-specific regulatory t-cell function in kidney transplant patients. Transplantation 2009, 87(3):376-383.
22. Mo C.B., Song W.L., Wang Z.P., Zheng J.M., Fu Y.X., Feng G., et al. The effect of the different immunosuppression therapy on CD4(+)Foxp3(+) Treg cells in kidney recipients. Zhonghua wai ke za zhi [Chinese J Surg] 2009, 47(22):1741-1743.
23. Fourtounas C., Dousdampanis P., Sakellaraki P., Rodi M., Georgakopoulos T., Vlachojannis J.G., et al. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. Am J Nephrol 2010, 32(1):1-9.
24. Bestard O., Cassis L., Cruzado J.M., Torras J., Franquesa M., Gil-Vernet S., et al. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl Int 2011, 24(5):451-460.
25. Vallotton L., Hadaya K., Venetz J.P., Buehler L.H., Ciuffreda D., Nseir G., et al. Monitoring of CD4+CD25highIL-7R (alpha) high-activated T cells in kidney transplant recipients. Clin J Am Soc Nephrol 2011, 6(8):2025-2033.
26. Zhao T., Yang C., Qiu Y., Xue Y., Zhao Z., Song D., et al. Comparison of regulatory T cells and FoxP3-positive T-cell subsets in the peripheral blood of renal transplant recipients with sirolimus versus cyclosporine: a preliminary study. Transplant Proc 2013, 45(1):148-152.
27. Hoerning A., Kohler S., Jun C., Lu J., Fu J., Tebbe B., et al. Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients. Clin Exp Immunol 2012, 168(2):251-259.
28. Levitsky J., Miller J., Wang E., Rosen A., Flaa C., Abecassis M., et al. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol 2009, 70(3):146-150.
29. Chu Z., Zhang J., Zhao Y., Ji Q., Zhong J., Zhang C., et al. Influence of immunosuppressive drugs on the development of CD4(+)CD25(high) Foxp3(+) T cells in liver transplant recipients. Transplant Proc 2010, 42(7):2599-2601.
30. Akimova T., Kamath B.M., Goebel J.W., Meyers K.E., Rand E.B., Hawkins A., et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012, 12(12):3449-3461.
31. Ekong U.D., Mathew J., Melin-Aldana H., Wang D., Alonso E.M. Successful resolution of inflammation and increased regulatory T cells in sirolimus-treated post-transplant allograft hepatitis. Pediatr Transplant 2012, 16(2):165-175.
32. Lange C.M., Tran T.Y.V., Farnik H., Jungblut S., Born T., Wagner T.O., et al. Increased frequency of regulatory T Cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin. Transpl Int 2010, 23(3):266-276.
33. Thornton A.M., Donovan E.E., Piccirillo C.A., Ethan M. Shevach IL-2 Is critically required for the in vitro activation of CD4+CD25+T cell suppressor function. J Immunol 2004, 172:6519-6523.
34. Fruman D.A., Klee C.B., Bierer B.E., Burakoff S.J. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA 1992, 89(9):3686-3690.
35. Shan J., Guo Y., Luo L., Lu J., Li C., Zhang C. Do CD4+Foxp3+ Treg cells correlate with transplant outcomes: a systematic review on recipients of solid organ transplantation?. Cell Immunol 2011, 270:5-12.
36. D'Addio F., Yuan X., Habicht A., Williams J., Ruzek M., Iacomini J. A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. Transplantation 2010, 90:260-269.
37. Kim J.I., O'Connor M.R., Duff P.E., Zhao G., Lee K.M., liades P.E. Generation of adaptive regulatory T cells by alloantigen is required for some but not all transplant tolerance protocols. Transplantation 2011, 91:707-713.
38. Liu Y., Chen Y., Liu F.Q., Lamb J.R., Tam P.K. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation. Transpl Int 2008, 21(5):483-494.
39. Ma A., Qi S., Wang Z., Massicotte E., Dupuis M., Daloze P. Combined therapy of CD4+CD25+ regulatory T cells with low-dose sirolimus, but not calcineurin inhibitors, preserves suppressive function of regulatory T cells and prolongs allograft survival in mice. Int Immunopharmacol 2009, 9(5):553-563.
40. Zhang W., Zhang D., Shen M., Liu Y., Tian Y., Thomson A.W. Combined administration of a mutant TGF-beta1/Fc and rapamycin promotes induction of regulatory T cells and islet allograft tolerance. J Immunol 2010, 185:4750-4759.
41. Muller Y.D., Mai G., Morel P., Serre-Beinier V., Gonelle-Gispert C., Yung G.P. Anti-CD154 mAB and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantation. PLoS ONE 2010, 5(4):e10352.
42. Gagliani N., Gregori S., Jofra T., Valle A., Stabilini A., Rothstein D.M. Rapamycin combined with anti-CD45RB mAB and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation. PLoS ONE 2011, 6(12):e28434.
43. Hester J., Schiopu A., Nadig S.N., Wood K.J. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 2013, 12(8):2008-2016.
44. Zeiser R., Dennis B., Leveson-Gower D.B., Kambham N., Beilhack A., Loh J. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111:453-462.
45. Golovina T.N., Mikheeva T., Suhoski M.M., Aqui N.A., Tai V.C., Shan X. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008, 181:2855-2868.
46. Lim D.G., Joe I.-Y., Park Y.-H., Chang S.H., Wee Y.M., Han D.J. Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells. Transpl Immunol 2007, 18:94-100.
47. Battaglia M., Stabilini A., Migliavacca B., Horejs-Hoeck J., Kaupper T., Roncarolo M.G. Rapamycin promotes expansion of functional CD4 +CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006, 177:8338-8347.
48. Guillot-Delost M., Cheraï M., Hamel Y., Rosenzwajg M., et al. Clinical-grade preparation of human natural regulatory T-cells encoding the thymidine kinase suicide gene as a safety gene. J Gene Med 2008, 10:834-846.
49. Pahwa R., Jaggaiahgari S., Pahwa S., Inverardi L., Tzakis A., Ricordi C. Isolation and expansion of human natural T regulatory cells for cellular therapy. J Immunol Methods 2010, 363:67-79.
50. Golovina T.N., Mikheeva T., Brusko T.M., Blazar B.R., Bluestone J.A., Riley J.L. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human t regulatory cells. PLoS ONE 2011, 6(1):e15868.
51. Coenen J.J.A., Koenen H.J.P.M., van Rijssen E., Hilbrands L.B., Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+subset of human CD4+CD25+ regulatory T cells. Blood 2006, 107:1018-1023.
52. Procaccini C., De Rosa V., Galgani M., et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity 2010, 33:929-941.
53. Passerini L., Allan S.E., Battaglia M., Di Nunzio S., Alstad A.N., Levings M.K. STAT5-signaling cytokines regulate the expression of FOXP3 in CD41CD251 regulatory T cells and CD4+CD25+ effector T cells. Int Immunol 2008, 20(3):421-431.
54. Singh A.K., Seavey C.N., Horvath K.A., Mohiuddin M.M. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response. Xenotransplantation 2012, 19(2):102-111.
55. Singh K., Kozyr N., Stempora L., Kirk A.D., Larsen C.P., Blazar B.R., et al. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am J Transplant 2012, 12(6):1441-1457.
56. Kopf H., de la Rosa G.M., Howard O.M., Chen X. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007, 7(13):1819-1824.
57. Stephan S., Bruno L., Hertweck A., Finlay D., Leleu M., Spivakov M. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci USA 2008, 105(22):7797-7802.
58. Haxhinasto S., Mathis D., Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+cells. J Exp Med 2008, 205(3):565-574.
59. Gabryšová L., Christensen J.R., Wu X., Kissenpfennig A., Malissen B., O'Garra A. Integrated T-cell receptor and costimulatory signals determine TGF-b-dependent differentiation and maintenance of Foxp31 regulatory T cells. Eur J Immunol 2011, 41:1242-1248.
60. Kim B.-S., Kim I.-B, Park Y.-J, Kim Y.S., Kim Y.J., Chang W.S. Conversion of Th2 memory cells into Foxp3+ regulatory T cells suppressing Th2-mediated allergic asthma. Proc Natl Acad Sci USA 2010, 107(19):8743-8747.
61. Kawamoto K., Pahuja A., Hering B.J., Bansal-Pakala P. Transforming growth factor beta 1 (TGF-β1) and rapamycin synergize to effectively suppress human T cell responses via upregulation of FoxP3+ Tregs. Transpl Immunol 2010, 23:28-33.
62. Bocian K., Borysowski J., Wierzbicki P. Rapamycin, unlike cyclosporine A, enhances suppressive functions of in vitro-induced CD4+CD25+ Tregs. Nephrol Dial Transplant 2010, 25:710-717.
63. Alice Long S., Buckner J.H. Combination of rapamycin and IL-2 increases de novo induction of human CD4+CD25+FOXP3+T Cells. J Autoimmun 2008, 30(4):293-302.
64. Procaccini C., De Rosa V., Galgani M., Carbone F., Cassano S., Greco D., et al. Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol 2012, 189(September (6)):2941-2953.
65. Asanuma S., Tanaka J., Sugita J. Expansion of CD4+CD25+ regulatory T cells from cord blood CD4+ cells using the common (-chain cytokines (IL-2 and IL-15) and rapamycin. Ann Hematol 2010, 90(6):617-624.
66. Qian X., Wang K., Wang X., Zheng S.G., Lu L. Generation of human regulatory T cells de novo with suppressive function prevent xenogeneic graft versus host disease. Int Immunopharmacol 2011, 11(5):630-637.
67. Singh A.K., Horvath K.A., Muhammad M. Rapamycin promotes the enrichment of CD4+CD25HiFoxP3+T regulatory cells from naïve CD4+ T cells of baboon that suppress anti porcine xenogenic response in vitro. Transplant Proc 2009, 41(1):418-421.
68. Bensinger S.J., Walsh P.T., Zhang J., Carroll M., Parsons R., Rathmell J.C. Distinct IL-2 receptor signaling pattern in CD4+ CD25+ regulatory T cells. J Immunol 2004, 172:5287-5296.
69. Zeng H., Yang K., Cloer C., Neale G., Vogel P., Chi H. mTORC1 couples immune signals and metabolic programming to establish T (reg)-cell function. Nature 2013, 499(7459):485-490.
70. Park Y., Jin H.S., Lopez J., Elly C., Kim G., Murai M., et al. TSC1 regulates the balance between effector and regulatory T cells. J Clin Invest 2013, 123(12):5165-5178.
71. Mizuki M.J., Schwable C., Steur C., Choudhary C., Agrawal S., Sargin B. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003, 101:3164-3173.
72. Liu G., Yang K., Burns S., Shrestha S., Chi H. The S1P1-mTOR axis directs the reciprocal differentiation of TH1 and Treg cells. Nat Immunol 2010, 11(11):1047-1057.
73. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 2011, 12(4):295-303.